PPBT — Purple Biotech Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Purple Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.8 | -21.8 | -20 | -7.28 | -26.5 |
| Depreciation | |||||
| Non-Cash Items | 1.6 | 1.57 | -0.419 | -2.94 | 19.8 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.744 | 3.25 | 0.274 | -4.33 | 0.808 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.3 | -16.7 | -19.9 | -14.4 | -5.66 |
| Capital Expenditures | -0.115 | -0.228 | -0.003 | 0 | -0.003 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 13.5 | 20.1 | 13.9 | 0.509 | 0.635 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 13.4 | 19.9 | 13.9 | 0.509 | 0.632 |
| Financing Cash Flow Items | -0.099 | -0.219 | -0.946 | -0.6 | -0.843 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.51 | 1.11 | 5.45 | 6.77 | 6.33 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.357 | 4.14 | -0.541 | -7.09 | 1.32 |